CORT vs. PRGO, HRMY, TARO, SUPN, XNCR, PCRX, OPK, ADCT, AVIR, and JAZZ
Should you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Perrigo (PRGO), Harmony Biosciences (HRMY), Taro Pharmaceutical Industries (TARO), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), Pacira BioSciences (PCRX), OPKO Health (OPK), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "pharmaceutical preparations" industry.
Corcept Therapeutics (NASDAQ:CORT) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Perrigo received 239 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 70.62% of users gave Corcept Therapeutics an outperform vote while only 66.75% of users gave Perrigo an outperform vote.
Corcept Therapeutics has a net margin of 22.38% compared to Perrigo's net margin of -0.17%. Corcept Therapeutics' return on equity of 24.19% beat Perrigo's return on equity.
In the previous week, Corcept Therapeutics had 5 more articles in the media than Perrigo. MarketBeat recorded 10 mentions for Corcept Therapeutics and 5 mentions for Perrigo. Perrigo's average media sentiment score of 1.23 beat Corcept Therapeutics' score of 0.96 indicating that Perrigo is being referred to more favorably in the news media.
Corcept Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.
93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 20.5% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.4% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Corcept Therapeutics has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corcept Therapeutics presently has a consensus target price of $40.10, indicating a potential upside of 27.46%. Perrigo has a consensus target price of $40.67, indicating a potential upside of 46.81%. Given Perrigo's higher possible upside, analysts plainly believe Perrigo is more favorable than Corcept Therapeutics.
Summary
Corcept Therapeutics beats Perrigo on 11 of the 17 factors compared between the two stocks.
Get Corcept Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corcept Therapeutics Competitors List
Related Companies and Tools
